pharmaceutical-market-research-reports-isr-v1

PHARMACEUTICAL MARKET RESEARCH REPORTS

Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of BioProcess Online. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.

ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available for to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.

TRENDS AND MARKET OUTLOOKS

  • Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 (3rd Edition)

    This market research report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years.

  • Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)

    This market research report goes into depth on the manufacturing aspect of biosimilars. Manufacturing these complex products in a cost efficient manner will be a critical component to successfully commercializing biosimilars and the anticipated boom.

  • Biologic Sterile Injectable Drug Product Manufacturing Market Overview and Outlook
    Biologic Sterile Injectable Drug Product Manufacturing Market Overview and Outlook

    This market research report provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents—all outsourcing decision-makers—predict the market will look like in 2022. Key statistics include development-stage and marketed product volume, the proportion outsourced, and the number...

  • Pharmaceutical Excipient Market Overview and Outlook
    Pharmaceutical Excipient Market Overview and Outlook

    This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.

  • Development vs Commercial Outsourced Manufacturing Practices: Biologics
    Development vs Commercial Outsourced Manufacturing Practices: Biologics

    This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.

  • Central Lab Market Dynamics and Outsourcing Performance (2019-2022)
    Central Lab Market Dynamics and Outsourcing Performance (2019-2022)

    This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.

QUALITY BENCHMARKING AND SERVICE PROVIDER PERFORMANCE

  • Bioanalytical Labs Market Dynamics and Service Provider Performance
    Bioanalytical Labs Market Dynamics and Service Provider Performance

    Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.

  • Biologic Drug Product Contract Manufacturer Quality Benchmarking
    Biologic Drug Product Contract Manufacturer Quality Benchmarking

    This report gives an-depth look at a subset of respondents from small and emerging biopharma companies. It will help small and emerging biopharmaceutical companies make more informed CMO decisions, and will help CMOs optimize operational and marketing strategies.

DEPARTMENT MODELS AND STRUCTURES

  • The CMC Function: Best Practices and Optimization
    The CMC Function: Best Practices and Optimization

    ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.

ISR ARTICLES

  • Understanding Your Customers’ Outsourced Service Roles And Responsibilities

    The Client – ISR was contacted by the vice president of content marketing at a Top 5, global CDMO with the question ‘How do we better understand our customers’ roles and responsibilities as they relate to outsourced contract manufacturing services?’ The client had three goals with this question. First, the client had drafted preliminary personas they wanted to refine and pressure test. Second, the client was interested in identifying the marketing channels their customers and prospects preferred to use so the client could tailor messaging for those media. Finally, the client wanted to get a better sense of decision-makers’ role in the outsourcing decision-making process. With this information, the organization’s content marketing team could ensure their budget and efforts were targeted in the most efficient and cost-effective manner.

  • How CDMOs Can Identify Their Customers' Decision-Making Process

    The Client – ISR was engaged by the Global Marketing Director at a Top 20 CDMO with the above question. The client had years of experience in marketing their brand to prospective customers but had recently begun to question the efficiency of their marketing spend. The client wanted to demonstrate to their company stakeholders that their marketing efforts were not only hitting the right targets, but that the language used in those efforts reflected their customers’ needs. Knowing this information would allow the client’s marketing department to move away from broad, product-based messaging focused on how good their services are, to messaging focused on how their services address their customers’ concerns.

  • How Can CROs Create Momentum In An Already Established Brand?

    The Client – ISR was approached by the Chief Marketing Officer at a Top 5 large, global CRO with the question ‘How do you create momentum in an already well-established brand?’ As the Chief Marketing Officer, our client was responsible for understanding and communicating to shareholders the current state of their brand. The client felt as if their brand had hit a ceiling and was feeling a sense of stagnation in their marketing efforts. Wishing to ensure continued brand growth, our client needed to know which components of their brand were succeeding and which may be falling short. With this information, our client would be able to tell how these dynamics would manifest themselves in the larger organization’s successes and failures.

  • Biologic Drug Substance Outsourcing

    In Q4 2020, ISR asked 112 outsourcers of biologic API about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated to strategic partnerships (38%) followed by tactical outsourcing (33%).

  • Large Molecule vs Small Molecule Drug Product Outsourcing

    In Q42020, ISR surveyed 110 sponsors who outsource biologic drug product manufacturing to gain insight into how drug product outsourcing is distributed at their organizations. 37% of respondents stated a larger proportion of biologic drug product manufacturing is outsourced compared to small molecule drug product. 39% said drug product manufacturing is outsourced at the same rate across molecule types.

ABOUT ISR VIDEO